Toledo, Ohio 43614


Purpose:

The investigators are intending to enroll Patients who are chronically treated with pyridostigmine for the treatment of any medical condition and presenting at the investigators' outpatient clinics for follow up appointment. Subjects taking pyridostigmine for the treatment of myasthenia gravis will be excluded. Both adults and children older than 12 years of age will be approached. Those subjects that agree to participate will be asked to sign an informed consent. For the participation of minors a parental (or guardian) consent and subject assent will be obtained. Those that participate will answer a few questions pertaining to their medical history and will then undergo electromyograph (CMAP) measurement with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the accessory nerve in the neck). Evoked electromyogram will be recorded on a computer hard drive. Eight percent or greater decrement in the CMAP response on repetitive stimulation will be considered positive.


Criteria:

Inclusion Criteria: - Subjects who have been taking pyridostigmine for the treatment of any condition Exclusion Criteria:


NCT ID:

NCT02364180


Primary Contact:

Principal Investigator
Shashi Bhatt, MD
The University of Toledo

Denise Zeller, RN
Phone: 419-383-6223
Email: denise.zeller@utoledo.edu


Backup Contact:

Email: christina.eisenhauer@utoledo.edu
Eisenhauer Christina, RN
Phone: 419-383-6784


Location Contact:

Toledo, Ohio 43614
United States

Shashi Bhatt, MD
Phone: 419-383-3556
Email: shashi.bhatt@utoledo.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.